-
Product Insights
NewLikelihood of Approval Analysis for Respiratory Distress Syndrome
Overview How likely is it that the drugs in Respiratory Distress Syndrome will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Respiratory Distress Syndrome Overview Respiratory distress syndrome (RDS) occurs in babies...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ANB-10 in Hemophilia A (Factor VIII Deficiency)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ANB-10 in Hemophilia A (Factor VIII Deficiency) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ANB-10 in Hemophilia A (Factor VIII Deficiency) Drug Details:...
-
Company Insights
NewMorgan Stanley – Digital Transformation Strategies
Morgan Stanley Digital Transformation Strategies Overview Morgan Stanley is utilizing AI and machine learning to improve its wealth and asset management operations and other operational processes. AI, big data, cloud, and blockchain are among the key technologies under focus for the company. The annual ICT spending of Morgan Stanley was estimated at $4.6 billion in 2023. A major share of this spending is earmarked for acquiring software, ICT services, and network and communications from vendors. Morgan Stanley is utilizing AI...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – IQ-DAA in Anthrax
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IQ-DAA in Anthrax report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IQ-DAA in Anthrax Drug Details: IQ-DAA is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DS-3939 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DS-3939 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DS-3939 in Solid Tumor Drug Details: DS-3939 is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – RO-7297089 in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RO-7297089 in Relapsed Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RO-7297089 in Relapsed Multiple Myeloma Drug Details: RO-7297089 (AFM-26) is under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – RO-7297089 in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RO-7297089 in Refractory Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RO-7297089 in Refractory Multiple Myeloma Drug Details: RO-7297089 (AFM-26) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DS-3939 in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DS-3939 in Metastatic Breast Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DS-3939 in Metastatic Breast Cancer Drug Details: DS-3939 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DS-3939 in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DS-3939 in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DS-3939 in Pancreatic Ductal Adenocarcinoma Drug Details: DS-3939 is under...